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The Polycomb gene BMI1 expression exerts a negative predictive impact on
several hematological malignancies, such as acute and chronic myeloid leukemia
(CML), myelofibrosis, and follicular lymphoma. As already demonstrated in CML,
BMI1 is responsible for the resistance to the tyrosine kinase inhibitors (TKIs) in a
BCR-ABL1-independent way. Even if, it is unknown where BMI1 in CML is expressed
(in progenitors or more mature cells). We decided, therefore, to evaluate if and where the
BMI1 protein is located, focusingmainly on the CD34+/CD38-/CD26+CML progenitors.
To begin we measured, by flow cytometry, the proportion of CD34+/CD26+ cells in
31 bone marrow samples from 20 CML patients, at diagnosis and during treatment
with imatinib. After that the bone marrow blood smears were stained with antibodies
anti-CD26, BCR-ABL1, and BMI1. These smears were observed by a confocal laser
microscope and a 3D reconstruction was then performed. At diagnosis, CD34+/CD26+
cells median value/µL was 0.48; this number increased from diagnosis to the third month
of therapy and then reduced during treatment with imatinib. The number and behavior
of the CD26+ progenitors were independent from the BCR-ABL1 expression, but they
summed up what previously observed about the BMI1 expression modulation. In this
work we demonstrate for the first time that in CML the BMI1 protein is co-expressed
with BCR-ABL1 only in the cytoplasm of the CD26+ precursors; on the contrary, in other
hematological malignancies where BMI1 is commonly expressed (follicular lymphoma,
essential thrombocytemia, acute myeloid leukemia), it was not co-localized with CD26
or, obviously, with BCR-ABL1. Once translated into the clinical context, if BMI1 is amarker
of stemness, our results would suggest the combination of the BMI1 inhibitors with TKIs
as an interesting object of research, and, probably, as a promising way to overcome
resistance in CML patients.
Keywords: BMI1, polycomb, BCR-ABL1, CML, CD26, leukemic stem cell
Galimberti et al. CD26 and BMI1 in CML
INTRODUCTION
Chronic myeloid leukemia (CML) is a hematological malignancy
characterized by the translocation between the chromosome
9 and 22, with the consequent generation of the BCR/ABL1
oncogene, responsible for increased proliferation, reduced
apoptosis, and uncontrolled enter into the bloodstream of the
immature myeloid cells (1).
After the introduction of the tyrosine kinase inhibitors (TKIs)
into the clinical armamentarium, the prognosis of CML has really
improved, with a survival target now comparable to that of age-
matched healthy subjects (2, 3). Nevertheless, about one third
of the patients during the treatment has to change the TKI for
occurrence of resistance or intolerance.
There are several mechanisms leading to the resistance, which
haven’t been well identified yet: in some cases, ABL1 mutations
impair the insertion of the TKI into the ATP-binding pocket
of the fusion protein (4), but in the majority the activation
of alternative pro-proliferating pathways, such as JAK-STAT, B-
catenin/Wnt, Hedgehog, or the abnormal epigenetic control, can
occur (5, 6).
It has been also reported that the hypoxic bone marrow niche
protects the leukemic stem cell (LSC) from the TKIs, blocking the
BCR-ABL1 protein synthesis (7). Moreover, BCR-ABL1 fusion
gene can still be detected by polymerase chain reaction (PCR) on
the genomic DNA in cases not expressing the fusion gene at the
mRNA level.
In this way we have the demonstration that LSC can still
survive in a quiescent status, even in subjects in deep molecular
response (DMR) (8).
Furthermore, the immunological control, including the KIR
haplotype (9) and the NK number/activation (10), seems to
collaborate to the maintenance of the treatment-free-remission
(TFR), which can be reached and maintained by half of patients
in persistent DMR (11, 12).
Once translated into the clinical context, these evidences
indicate a right way to reach the CML eradication: the
addition of TKIs to further drugs able to modify the bone
marrow microenvironment or to block the alternative pathways
sustaining the LSC survival.
Regarding the LSC identification, in 2014 Hermann and
colleagues identified the enzyme dipeptidyl-peptidase-IV
(DPPIV/CD26) as a specific marker of the CD34+/CD38-
leukemic progenitors, demonstrating in a murine model that
these cells were able to summarize the CML onset and that
they decreased remarkably during the successful treatment with
imatinib (13).
CD26 is able to disrupt the SDF-1-CXCR4-axis, thus
detaching the LSCs from the bone marrow niche and increases
cell cycling so leading to an increased ability to be targeted by
TKIs.
It is very interesting to notice that CD26 antigen is not
detectable in normal hematopoietic progenitors or in cells
from other hematological malignancies, including acute myeloid
leukemia (14).
Our group has also recently measured, by flow cytometry,
the CD34+/CD26+ LSCs in bone marrow and peripheral blood
from CML patients at diagnosis, during treatment with TKIs and
in TFR, confirming that CD26 is a CML-specific marker (15).
Interestingly, CD26 was also expressed by a small part of patients
in TFR, suggesting that the BCR-ABL1 transcript measure in the
peripheral blood is not always enough to understand the behavior
of the LSC in the bone marrow niche, cell that could sustain the
loss of DMR or cause the resistance to TKIs.
About the BCR-ABL1-independent mechanisms of resistance,
we previously focused on the epigenetic control, showing that
time to complete cytogenetic response and event-free survival of
patients receiving imatinib were negatively conditioned by the
expression of some Polycomb genes. In particular, high levels of
BMI1, an oncogene highly expressed in acute myeloid leukemia
and in advanced phases of CML, were connected to a poorer
outcome, whereas on the other side a high expression of CBX6
and CBX7 played a favorable role (16).
With these premises, we decided to combine the two relevant
LSC markers (CD26 and the BMI1) (17), in order to test if they
were co-expressed in CML progenitors. Indeed, the possibility of
finding a co-expression of BMI1 and CD26 in CML-LSC could
have as clinical consequence the possibility of using the BMI1
inhibitors (today available for the clinical use) for attempting to
eliminate LSCs and eventually overcome the resistance to TKIs.
For this purpose, we analyzed, by the confocal microscopy, the
expression of CD26, BCR-ABL1 P210, and BMI1 proteins in bone
marrow samples from 20 CML patients.
PATIENTS AND METHODS
Patients
Overall, 31 bone marrow samples from 20 patients affected by
CML at diagnosis or during the first 12 months of treatment with
imatinib were assessed, by flow cytometry, for the presence of
CD34+/CD38-/CD26+ cells.
Overall, 21 samples showed CD34+/CD26+ cells in the bone
marrow (negative cases were observed after 6 and 9 months of
therapy); among them 9 samples with the highest CD26+ values
have been then tested for the co-expression of CD26, P210, and
BMI1 proteins by the confocal microscopy.
The BCR-ABL1/ABL1 ratio wasmeasured by quantitative PCR
on the concomitantly harvested peripheral blood, according to
the standardized operative procedures edited in 2016 by the
Italian cooperative group GIMEMA LabNET (www.gimema.it/
labnet-cml/).
A minimum of 20,000 ABL1 copies was necessary to consider
a sample as “evaluable”; 32,000 ABL1 copies were necessary to
define the MR4.5 or 100,000 ABL1 copies for MR5, according to
the ELN guidelines (18).
The enrolled patients were consecutively observed at the
Hematology units of Pisa, Milano, Siena, Reggio Calabria, and
Roma (Italy) and enrolled only on the basis of their acceptance
to take part to the study. Each of them signed an informed
consent to donate the residues of the material harvested for the
routine diagnostic tests for further no-profit scientific purposes.
This informed consent was previously approved by the respective
Ethical Committees.
The clinical characteristics of patients are reported in Table 1.
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TABLE 1 | Clinical characteristics on the 20 patients enrolled into the study.
Clinical feature n (%)
Patients 20
Age (median/range) 64 (56–79)
SEX
M 11 (55)
F 9 (45)
SOKAL RISK SCORE
Low 7 (35)
Intermediate 9 (45)
High 4 (20)
TKI
Imatinib 20 (100%)
Flow-Cytometry Assay
For each patient 2mL of bone marrow samples collected
in EDTA tubes were analyzed. CD26 expression was
assessed by multiparametric flow cytometry, analyzing the
CD45+/CD34+/CD38− population using a four-color protocol,
as previously reported by our group (15). Briefly, 2.0 x 106
leucocytes were incubated with BD Pharmigen CD45-V500
(clone 2D1), CD34-FITC (clone 581), CD38-APC (clone HIT2),
CD26-PE (clone M-A261), and proper negative controls. After
washing, acquisition and analysis of at least 1.0 × 106 of CD45+
cells were performed by using aMACSQuant Analyzer (Miltenyi,
Gemany), equipped with 3 lasers and 8 fluorescent channels
available. The absolute number of CD26+ cells was calculated by
multiplying the number of white cells/µL automatically counted
for the proportion of CD34+/CD38−/CD26+ on CD45+ cells
using the MACSQuantify Software (Miltenyi).
Immunofluorescence Assays
Triple-Immunofluorescence
From each sample, 4 smears were prepared using the bone
marrow, then fixed in cold acetone/methanol (1:1 v/v) for 10min
at −20◦C, washed in phosphate buffered saline (PBS 1x), and
treated for 10min with 0.2% triton-X100/PBS. After 1 h in
blocking solution (BS, 0.1% Tween, 0.25% BSA in PBS), slides
were incubated overnight at 4 ◦C with the following primary
antibodies diluted in BS at optimal working dilutions, determined
empirically by means of serial dilutions: MαBCR/ABL1 (1:300,
Thermo Fisher, Rockford, IL, USA), RαBMI-1 (1:100, Thermo
Fisher), and GαCD26 (1:100, R&D system, Minneapolis, MN,
USA). Slides were then washed three times in BS and incubated
in the dark with fluorescent conjugate secondary antibodies
diluted 1:250 in BS; a first incubation of 90min with DαR and
DαG antibodies (Alexa Fluor R© 568 and Alexa Fluor R© 647, Life
Technologies, Monza, Italy) was performed.
After three washes in BS, a second incubation for 90min
with GαM antibody (Alexa Fluor R© 488 Life Technologies Italia)
was made. The slides were sequentially washed in BS, PBS 1x,
and finally mounted in mounting medium with DAPI (Sigma-
Aldrich, St. Louis, MO, USA). All steps were performed at room
temperature unless otherwise specified. The samples were then
observed at 20x, 43x, or 63x magnification with a confocal laser
scanning microscope (TC SSP8 Leica Microsystems, Mannheim,
Germany) using 488-nm, 561-nm, and 642-nm excitation
wavelength lasers.
Negative controls for secondary antibodies were
performed omitting primary antibodies. The analysis of
immunofluorescence pattern was performed in at least three
fields per smear for each sample. Confocal multiple optical
sections (z-step = 0.35µm) were used to obtain the maximum
intensity projections and the iso-surface representation.
In addition, as disease-negative controls, 2mL of bone
marrow from one patient with essential thrombocytemia, one
with hypereosinophilia, two with MGUS, one with multiple
myeloma and one with non Hodgkin’s follicular lymphoma were
also assessed.
Statistical Analysis
All statistical analyses were carried out using the SPSS software,
version 22.0 (SPSS, IBM, Bologna, Italy). In all computations, the
level of significance was set at p < 0.05.
To analyze differences in the levels of each single variable, we
employed the Mann–Whitney U- and the Wilcoxon-tests. The
Kendall one-tail correlation test was used to detect relationships
between two measurable variables and the t-test for comparison
of mean values. For comparison of the median values, the
median test was adopted. The linear regression was adopted for
comparing CD34+ and CD26+ values.
RESULTS
Patients’ Characteristics and
CD34+/CD26+ Myeloid Progenitors
Before evaluating the expression of the BMI1 protein in
CD34+/CD26+ progenitors (whose CML identity was
confirmed by the BCR-ABL1 protein expression in order to
avoid the mature CD26+ lymphocytes), we identified among the
31 samples from the 20 patients enrolled into the study those
with measurable levels of CD34+/CD26+ precursors.
In 21 samples we were able to detect and measure the
CD34+/CD26+ cells; all samples at diagnosis and 11 during the
follow-up were positive, whereas 10 cases harvested at 6 and 9
months resulted negative. Among these samples CD26-positive,
we chose for the microscopic analysis 9 samples with the highest
CD26/uL levels.
The median age of the enrolled patients (11 men and 9
women) was 64 years (range, 56–79). At diagnosis, all of them
were in chronic phase; the median number of blasts in the bone
marrow was 4%; the Sokal risk score was high in 4, intermediate
in 9, and low in 7 cases. All patients received imatinib as first
line of therapy and during the study. Clinical characteristics of
patients are detailed in Table 1.
All patients enrolled were tested at diagnosis; during the
follow-up, 13 bonemarrow samples were harvested by 12months
of therapy.
Firstly, we used flow cytometry to identify and measure the
CD34+/CD38− cells on the samples at diagnosis: their median
value was 130/uL (range, 24–810). After 3 months of imatinib,
the median value of the CD34+/CD38− progenitors was 14.4
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FIGURE 1 | The Figure represents the median values of CD34+/CD38- and
CD34+/CD26+ progenitors at diagnosis and during treatment with imatinib;
for a better understanding, the values of CD26+ cells have been multiplied by
ten.
(range, 0.21–575); after 6 months, 78.1 (range, 15.7–1250); after 9
months, 41.1 (range, 4.4–397); after 12 months, 73.8 (range, 0.1–
503). The values at 15 months were not computed, because of the
small number (2 patients were evaluated at this time-point).
After the median test, no statistically significant differences
were noticed for the value of CD34+ cells/uL among the different
considered time-points.
Then, we measured the CD34+/CD38-/CD26+ fraction: at
diagnosis, its median value was 0.33/uL (range, 0.9–12.05). After
3 months of imatinib, the median value increased up to 2.01
(range, 1.56–13.9); after 6 months, to 2.87 (range, 0.48–5.23);
after 9 months, the median number of CD26+ cells decreased to
0.11 (range, 0–2.52); after 12 months, it was 0.23 (range, 0–0.26).
The difference measured between the month +6 and the
month +12 resulted statistically significant (2.87/uL after 6
months of imatinib vs. 0.23/uL; after 12 months; p= 0.04).
The behavior of CD34+/CD38- and CD34+/CD38-/CD26+
progenitors is represented in the Figure 1.
When linear regression was performed between CD34+ and
CD26+ values, as expected, a significant correlation was found
(p= 0.008).
On the contrary, when we assessed if the number of the
CD26+ progenitors in bone marrow was correlated with the
BCR-ABL1 mRNA expression assessed in the peripheral blood,
no significant relationship has been found (R = 1.42; R2 = 0.20;
p= 0.54; see Figure 2).
As above reported, at diagnosis (where BCR-ABL1/ABL1 ratio
has been conventionally considered as 100%) the median value
of CD26+ progenitors was 0.33/uL. It is interesting to note that
in 3 cases the CD26+ value at diagnosis was inferior in respect
of the median one; in 2 of these 3 cases, also the values of
CD34+/CD38- cells were very low (65 and 24/uL vs. the median
= 130/uL). Interestingly, these two cases revealed as optimal
responders, because both reached either the early molecular
response or the MR4 by the 12th month.
FIGURE 2 | Linear regression curve: CD34+/CD26+ number is not
significantly correlated with BCR-ABL1/ABL1 expression, either at diagnosis or
during follow-up. R2 = 0.20; p = 0.54.
In our series, only one patient developed a blastic phase,
concomitantly to the detection of T315I compound mutation.
Nevertheless, at the time of this study, he was still in response,
showing a low number of CD26+ cells.
The behavior of the median number of CD26+ progenitors
from the bone marrow and of the BCR-ABL1/ABL1 ratio
measured in the peripheral blood of the whole series (box A), of
a “optimal” case (box B) and of a “warning” subject (box C) are
represented in the Figure 3.
Finally, the number of CD26+ cells measured at
the different time-points was not associated to the
clinical characteristics of our patients (sex, age, or
Sokal risk).
CONFOCAL MICROSCOPY
For the microscopy analysis, we selected 9 samples showing the
highest number of CD34+/CD26+ precursors (median value,
3.13/uL, range 1.56–13.09).
As shown in Figure 4A, which represents one of the CML
cases, the BMI1 protein (in red) was co-expressed with CD26+
(in gray) and with the P210 (in green).
Noteworthy, the blue nuclear staining by DAPI identified in
the bone marrow smear the presence of some CD26- cells that
resulted both P210- and BMI1-negative.
In the B box of the same figure, the tridimensional confocal
microscope analysis showed that the 3 target proteins were co-
localized in the cytoplasm of the CD26+ LSC (Figure 4B).
This finding characterized all the 9 tested samples.
Figure 5 shows the merged staining for CD26, P210, and
BMI1 in a patient affected by acute myeloid leukemia (A), in
one subject with essential thrombocytemia (B), and in one case
affected by follicular lymphoma (C). As clearly shown, in these
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FIGURE 3 | The Figure represents the median values of CD26+ cells and of the BCR-ABL1/ABL1 transcript at diagnosis and during treatment with imatinib in the
whole series (box A), in an “optimal” case (box B), and in a “warning” case (box C).
Philadelphia-negative cases BMI1 antigen was present, but only
in a small percentage of CD26- cells.
On the contrary, BMI1 was co-localized in CD26+ cells from
all CML samples, as represented in the Figure 6.
This is in accordance to data already reported in literature,
where BMI1 positivity has been described in AML blasts, in Ph’-
negative chronic myeloproliferative neoplasias, and in follicular
lymphoma.
Therefore, our work clearly demonstrates that BMI1 protein
can be present in several hematological malignancies, but that
only in CD26+ cells (thus CML LSCs) it is co-expressed with the
BCR-ABL1 fusion protein.
DISCUSSION
The Polycomb genes have been reported to play a relevant
pathogenetic and predictive role across multiple cancers,
including the hematological ones. In acute myeloid leukemia,
BMI1 is over-expressed, while other genes from the same
family, such as CBX6 and CBX7, are down-regulated (19). In
myelodysplastic syndromes and in clonal hematopoiesis (CHIP),
EZH2 and TET2 have been reported to be associated with higher
rate of cardio-vascular events (20), and TET2 mutations (at
low allelic burden) seem to positively predict the response to
azacitidine (21).
In Ph’-negative chronic myeloid neoplasms, BMI1 seems to
be correlated with a higher degree of bone marrow fibrosis (22).
Finally, in follicular lymphoma, BMI1 represents a significant
poor factor in terms of overall survival (23). Therefore, in
hematology, BMI1 acts as a “bad” gene, and it could represent
an interesting and promising target for new therapies.
In other neoplasias, such as the breast cancer, the BMI1
knock-down is able to increase the expression of several tumor-
suppressive miRNAs (miR-200a, miR-200b, miR-15a, miR-429,
miR-203), with the consequent reduced expression of N-
Cadherin, Vimentin, and β-Catenin, thus resulting in a decreased
invasion, migration and proliferation of the neoplastic cells (24).
In an in vitro leukemia model, two BMI1 inhibitors, PTC-
209 and PRT-4165, down-regulating the expression of NOTCH1,
HES1, and c-MYC, were able to block the leukemic cells
growth, suggesting that the BMI1 inhibitors can be good
candidates against leukemia (25). Finally, in multiple myeloma,
PTC-209 showed a synergistic activity when combined with
other epigenetic inhibitors (such as those targeting EZH2 and
BET) (26).
With these premises, we supposed that the epigenetic control
exerted by the Polycomb family genes could be at least one
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FIGURE 4 | Confocal laser scanning microscopy: representative images of a bone marrow smear from one of the 9 CML patients enrolled into the study. (A)
Bidimensional images of the maximum intensity projection. Scale bars 10µm. From the right to the left: in blue, the nuclei; in gray, the CD26+ cells; in green, cells
expressing BCR-ABL1. The merged imagines show that CD26+ cells co-express both BMI1 and BCR-ABL1. (B) 3D-reconstruction of the merged imagines: BMI1
and BCR-ABL1 are co-expressed in the cytoplasm of the CD26+ cells.
FIGURE 5 | Confocal laser scanning microscopy: representative images of bone marrow smears from patients with acute myeloid leukemia (A), essential
thrombocytemia (B), and follicular lymphoma (C). Scale bars 10µm. Reactions for BMI1 (red), BCR-ABL1 (green), and CD26 (gray). It is clear that in these
malignancies only BMI1 is expressed. As expected, these diseases are all CD26- and BCR-ABL1-negative.
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FIGURE 6 | Confocal laser scanning microscopy: representative images of a bone marrow smear from one of the 9 CML patients enrolled into the study with a high
representation of CD26+ cells. Bidimensional images of the maximum intensity projection. Scale bars 50µm. From the right to the left: in blue, the nuclei; in pink, the
CD26+ cells; in red, the BMI1+ cells. Cluster of cells marked by the arrows co-expressed CD26 and BMI1 antigens.
of the causes of the resistance to TKIs in CML: as we
have already demonstrated in our previous work BMI1 could
represent a new valid, predictive marker of response to imatinib,
independently from the BCR-ABL1 behavior or ABL1 mutations
(16). In particular, the BMI1 expression initially increased
notwithstanding the reduction of the BCR-ABL1 transcript,
probably because of the precocious elimination of the more
sensitive leukemic cells (that could be those carrying lowest BMI1
levels). After the third month of treatment, the values of BMI1
expression well correlated with the molecular response, and high
BMI1 levels did negatively impact on the event-free-survival.
Nevertheless, our pivotal work did not answer the question
about which kind of cells in CML would express BMI1; with the
purpose to solve this clue, we designed the present study, whose
aim was to find if the CD26+ cells, in the meanwhile identified as
the true LSC, were the “reservoir” of this protein.
Also if conducted on a small series of patients, we showed that
in CML the BMI1 protein was co-expressed with the P210 only
in the cytoplasm of the CD26+ cells.
On the other hand, as expected, BMI1 was also detected in
other myeloid and lymphoid tumors (essential thrombocytemia,
acute myeloid leukemia, follicular lymphoma), but in all these
cases it was never co-expressed with CD26 nor, obviously, with
P210.
This could suggest that in CML BMI1 could be considered, in
addition to the CD26, as a potential marker of stemness.
Unfortunately, we did not perform a quantitative estimation
of the BMI1 protein (the confocal microscopy is not a
quantitative technique), but it is very intriguing to observe
that the CD34+/CD26+ progenitors number increased
from diagnosis to the sixth month of treatment, while the
overall CD34+ elements and the BCR-ABL1 transcript
decreased, analogously to that we observed about the BMI1
expression.
This could be probably explained by the more rapid and
effective action exerted by imatinib on the more mature cells in
comparison with the CD26+ progenitors.
Moreover, in our study we did not find any significant
correlation between CD34+/CD26+ cells and BCR-ABL1mRNA
expression; this observation could confirm that coming from
another work published by our group, where CD26+ cells
have been detected even in subjects in DMR and during TFR,
independently from the TKI used (15).
From the technical point of view, it is well known that at
diagnosis the BCR-ABL1/ABL1 ratio is underestimated for the
higher amount of ABL1 gene, either “normal” or “pathological,”
and that GUS could be a better reference gene (27), but this
technique has not been standardized yet in the Italian network,
and thus we considered for all patients at diagnosis a BCR-
ABL1/ABL1 ratio of 100% IS. Nevertheless, also when we
focused the statistical analysis only on the follow-up samples, no
significant relationship between the number of CD34+/CD26+
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cells in the bone marrow and the BCR-ABL1 expression in the
peripheral blood was found.
This observation, even if as an indirect proof and performed
only in a small series of cases, could prompt us to hypothesize that
(1) BMI1 is specifically expressed by the CML CD26+ LSC, and
(2) because of its BCR-ABL1-independent behavior, BMI1 could
be considered as one of the mechanisms of resistance to TKIs,
that would make this gene an interesting therapeutic target for
new drugs in the CML landscape.
At last the recent availability of the PTC-596, a BMI1 inhibitor
is now being tried against the ovarian cancer (ClinicalTrials.gov
Identifier: NCT03206645) and the possibility to realize further
in vitro and in vivo models with cells where BMI1 could be
silenced (for example by the CRISPR approach) probably will
give us further demonstration about of a possible translation of
our pivotal findings in the clinical scenario of the CML.
Obviously, additional ex vivo experiments conducted on
larger series of CML patients and with the second- and third-
generation TKIs are required to evaluate the potential usefulness
of combining the BMI1 inhibitors with TKIs in resistant cases.
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